April 2013 in “The Journal of Urology” Researchers created a simple tool to predict bladder blockage from prostate enlargement using urine flow rate and prostate volume.
March 2013 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Prostate cancer screening doesn't significantly reduce death rates and has risks like overdiagnosis and side effects.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
January 2026 in “Clinics and Practice” Baricitinib helps alopecia areata and may improve psoriasis, but its effect on psoriatic arthritis is unclear.
June 2025 in “Preprints.org” Baricitinib improves alopecia areata and may help psoriasis but might not be ideal for psoriatic arthritis.
223 citations
,
September 2018 in “Rheumatology” JAK inhibitors are effective in treating various immune-related diseases, not just rheumatoid arthritis.
August 2025 in “Psychiatry Neurology and Medical Psychology” Mental health issues affect adaptation in alopecia patients more than the cause of hair loss.
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab is safe for long-term use with low rates of major heart-related events.
March 2015 in “Polish Journal of Public Health” Blood vessel patterns in skin diseases relate to certain blood markers in systemic sclerosis but not in psoriasis or psoriatic arthritis, and may indicate circulation issues in alopecia.
January 2011 in “Reactions Weekly” St. John's Wort may reduce the effectiveness of finasteride by increasing its breakdown in the body.
January 2010 in “CommonKnowledge Research Repository (Pacific University Oregon)” Finasteride can't be recommended for cancer prevention due to concerns about high-grade cancer risk.
77 citations
,
May 2012 in “Expert Opinion on Emerging Drugs” New treatments for male hypogonadism are effective and should be personalized.
75 citations
,
May 1986 in “Clinics in endocrinology and metabolism” Male hormones are important for hair and oil gland development and can cause conditions like excessive hair growth and acne.
60 citations
,
June 1997 in “Drugs & Aging” Mitoxantrone with a corticosteroid helps manage symptoms for some advanced prostate cancer patients but doesn't extend life.
24 citations
,
October 2008 in “International Braz J Urol” Lovastatin doesn't improve lower urinary tract symptoms treatment.
24 citations
,
January 1996 in “The Prostate” Finasteride is a safe and effective long-term treatment for prostate enlargement, reducing prostate volume and related symptoms.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” Most treatments for spondyloarthritis are safe, but monitoring and careful selection based on patient risks are important.
17 citations
,
November 1997 in “Andrology” Finasteride effectively treats enlarged prostate and male baldness, improves symptoms of hirsutism in women, but doesn't work for acne, and may delay prostate cancer progression with few side effects.
11 citations
,
December 2010 in “The Journal of Urology” Taking oral testosterone with or without dutasteride increases testosterone levels and could be an effective treatment for low testosterone.
8 citations
,
October 2022 in “Dermatology practical & conceptual” Tofacitinib and ruxolitinib are effective and safe for treating various autoimmune skin and joint disorders.
4 citations
,
November 2022 in “British Journal of Cancer” Men with melanoma have a higher risk of later being diagnosed with prostate cancer.
4 citations
,
December 2013 in “Archivio italiano di urologia, andrologia” Dutasteride reduces hospitalization and prostate cancer risk compared to finasteride, potentially offsetting its higher cost.
3 citations
,
October 2011 in “QJM” The drugs finasteride and dutasteride reduce low-grade prostate cancers but may double the risk of high-grade cancers.
3 citations
,
August 1996 in “PubMed” Finasteride reduces prostate size and serum levels, helping manage benign prostatic hyperplasia, without affecting prostate cancer detection. Regular monitoring is needed for users.
1 citations
,
October 2009 in “Cancer Epidemiology Biomarkers & Prevention” Cancer prevention is crucial, with a focus on research and improved screening methods.
February 2026 in “European journal of medical research” Combining α-blockers with 5α-reductase inhibitors improves symptoms and outcomes for severe benign prostatic hyperplasia.
November 2022 in “The journal of investigative dermatology/Journal of investigative dermatology” Ivermectin 1% cream effectively reduces visible and invisible symptoms of rosacea.
Finasteride reduces prostate size, improves urination, and slows prostate cancer progression.
5-Alpha reductase inhibitors help treat enlarged prostate but may cause sexual side effects.
September 2013 in “Cancer Discovery” Finasteride is safe for long-term use in prostate cancer treatment.